  - FTC will clear Teva-Cephalon merger with certain conditions
The Federal Trade Commission set conditions for approving Teva Pharmaceutical Industries' $6.8 billion takeover of Cephalon. Teva must divest a cancer-pain medicine and an extended-release muscle relaxant, the commission said. The FTC also is requiring Teva to grant other drugmakers marketing rights to Cephalon's sleep-disorder drug Provigil next year. Google/Agence France-Presse (10/8)        | SBE’s Conference on Electrofuels Research will be held November 6-9 in Providence, RI, and will bring together the nation's energy innovators: engineers, scientists, corporations, and government officials to discuss unique research strategies in developing ways to make transportation fuels. Visit electrofuels.aiche.org for more information. | - Study: 2 types of HIV are present in cerebrospinal fluid
Scientists at the University of North Carolina's Chapel Hill School of Medicine reported in the journal PLoS Pathogens that they discovered two types of HIV in the cerebrospinal fluid of patients with HIV-related dementia. They also found that one of the newly identified HIV types is present in macrophages, a type of immune cell. They said the findings might help pinpoint patients at higher risk for the condition and help scientists better understand why anti-retroviral drug cocktails prevent HIV-linked neurological conditions in some patients. USA TODAY/HealthDay News (10/7) - Experts find genetic variants linked to melanoma
Two teams of scientists analyzed the DNA of patients with melanoma and found mutations in four single nucleotide polymorphisms, or SNPs, that appear to increase the risk of the skin cancer. The findings in the journal Nature Genetics might help shed light on the development of the disease and lead to better treatments for it. ABC (Australia) (10/10) - Neural stem cells may be key in diabetes treatment
Transplanting neural stem cells from the hippocampus and olfactory bulb to the pancreas helped improve insulin production and reduce blood glucose levels in rats with diabetes, according to a study in EMBO Molecular Medicine. Experts said using the patients' own neural stem cells may address shortages in insulin-producing cells without the need for gene transfer to bolster diabetes treatment. Yahoo!/Asian News International (10/7) - Experts ID gene linked to severe hypoglycemia
A study in the journal Science found that mutations in the AKT2 gene, which signals insulin transmission in the body, resulted in a continuous reduction in blood glucose levels in patients with severe hypoglycemia. However, cancer treatments that block AKT1 gene may also hold promise for addressing AKT2 gene mutations associated with the condition, researchers said. BBC (10/6), eMaxHealth.com (10/7)  | LET’S GO DESIGN: Episode #5
In this episode of SolidWorks’ interactive web series, Jeremy moves closer to the final design of our Hot Rod Baby Buggy and also hot-wires the golf cart motor to show how the aluminum tracks perform flawlessly. Watch at LetsGoDesign.tv. |
 | Company & Financial News |  |  | | - Tengion's interim CEO has high hopes for regenerative medicine
Tim Bertram, Tengion's chief scientific officer and acting CEO, said he believed that the time of regenerative medicine has come and that the technology will continue to thrive in the coming years. At the Regenerative Medicine Roundtable, Bertram said companies should focus on the commercial applications of products in order to draw funding. Abner Mhashilkar, medical translational officer at the Wake Forest Institute for Regenerative Medicine, said there was available funding for regenerative medicine firms but that most venture capitalists expect to see a return on investment within five to six years. MedCityNews.com (10/7) - Officials expect biotech sector in Florida's Treasure Coast to flourish
Local officials say they believe the biotech industry in the Treasure Coast region of Florida will prosper in the next 10 years, despite the slow economy, competition for government grants and other challenges. Larry Pelton, president of the Economic Development Council of St. Lucie, said he expected the emergence of five biotech firms in the next five years and the creation of up to 5,000 jobs in the region. TCPalm.com (Fort Pierce, Fla.) (10/7)  | Earn 2X rewards points on advertising costs with The New Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, shipping
• 1X points on everything else
• For a limited time, 50K bonus points when you spend $10K your first 5 months
LEARN MORE AND APPLY |
 
| Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | |  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - BIO argues for a 21st century FDA
In this issue of FDLI's Food and Drug Law Policy Forum (Volume 1, Issue 18), James C. Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), answers this provocative question: Can a 21st Century FDA Accelerate Biotech Innovation to Cure Disease and Save Lives? Greenwood argues that Congress needs to elevate the agency to independent status (like EPA); that FDA must advance regulatory science and innovation through a chief innovation officer; and that FDA should enable modernized patient-centric clinical development, all to make FDA a truly effective regulatory agency. Read the article here.
| SmartQuote | | | |  | We shall not cease from exploration, and the end of all our exploring will be to arrive where we started and know the place for the first time."
--T.S. Eliot, American-British writer, quoted for Columbus Day, Oct. 10, 2011  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, October 07, 2011
- Thursday, October 06, 2011
- Wednesday, October 05, 2011
- Tuesday, October 04, 2011
- Monday, October 03, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment